Weather Tonight: 4°c Partly Cloudy Night Morning: 8°c Cloudy

Business

astrazeneca

AstraZeneca’s Seroquel gets closer to a green light in US

Lucy Tobin
11 Jun 2009


Pharmaceuticals giant AstraZeneca today received a boost when the US drug watchdog took the first steps to approve its $4.5 billion anti-psychotic medicine Seroquel for use by children.

Mayfair-headquartered AstraZeneca, the UK's second-largest drug firm, had asked the US Food and Drug Administration to approve Seroquel as a treatment for children and teenagers suffering from schizophrenia and bipolar mania in October.

For today's decision advisors to the FDA said that the drug appears “safe” and “effective” for children, and the watchdog is now expected to clear them for paediatric use. Pfizer's Geodon and Eli Lilly's Zyprexa were also given the board's backing.

The market for anti-psychotic drugs is growing, especially in the US where sales topped $14 billion last year. For AstraZeneca, Seroquel is the second-best selling drug in its portfolio, but its reputation was hit last month when leaked emails, revealed as part of a law suit, suggested the pharma firm was trying to push Seroquel for uses that were not approved by safety regulators.

The drug giant is being sued by 16,000 American patients for “spinning, skewing and concealing” information on the medicine's potential side-effects.

Reader views (1)

 Add your view

Eli Lilly Zyprexa can cause diabetes

I took Zyprexa a powerful Lilly schizophrenic drug for 4 years it was prescribed to me off-label for post traumatic stress disorder was ineffective costly and gave me diabetes.
This is a powerful drug that can damage a young person physiologically for life.

Please take with caution and learn as much as you can about side effects.
Eli Lilly's #1 cash cow Zyprexa drug sale $38 billion dollars so far,has a ten times greater risk of causing type 2 diabetes over the non-user of Zyprexa.
So,here we have a conflict of interest that this same company also is a big profiteer of diabetes treatment.

Daniel Haszard

- Daniel Haszard, Bangor Maine USA, 11/06/2009 12:56
Report abuse


Add your comment

 

Terms and conditions Make text area bigger You have  characters left.

We welcome your opinions. This is a public forum. Libellous and abusive comments are not allowed. Please read our House Rules.

For information about privacy and cookies please read our Privacy Policy.


 

 

  • Slump looms in eurozone as economy takes a dive Euro Europe's lingering debt crisis has pushed the eurozone closer to recession as the beleaguered single currency bloc's economy shrank for the...
  • Sports Direct is on right track Mike Ashley Sports Direct is on track to hit its "super-stretch" profit targets this year, passing the first hurdle that could see it hand founder Mike...
  • Bank may turn off printing presses as inflation drops Mervyn King The Bank of England's latest £50 billion burst of quantitative easing may be the last time it needs to resort to the printing presses
  • Online orders on mobiles lift Domino's Pizza Domino's Pizza UK said its online sales have powered ahead to account for more than half of delivered sales
  • Debt deadline: Greece on brink Greek protests Hopes were rising that Greece will sign up to the first €130 billion (£109 billion) bailout from the European Union and International...
  • Frothy profits at Heineken Beer The economy might be in dire straits but Brits still love a pint down the pub
  • French banks face battering on exposure to Greek debt Jean-Laurent Bonaffé French banks look set to take one of the biggest haircuts on Greek debt as the country's largest, BNP Paribas, has said it had raised its...
  • Thorntons calls in a former Gunner to help turnaround Keith Edelman The chocolatier Thorntons has turned to the former boss of Arsenal football club to turn around its fortunes
  • LandSecs £1bn joint venture for Victoria A £1 billion-plus redevelopment is on the way at Victoria station
  • Morgan Crucible results surge on emerging market growth Morgan Crucible reported highest-ever full-year results, helped by strong performance across both its divisions, and reiterated that 2012 growth would be driven by new products and emerging markets
  •  
    Market Roundup
    WEDNESDAY UPDATE

    Barclaycard's exit leaves CPP with an identity crisis

    Bye bye Barclaycard. Nearly a year since the FSA started investigating CPP over its sales techniques, the identity theft protection firm touched a new, all-time low today after admitting it was losing one of its most high-profile clients

    More